These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 14643298)

  • 21. Genetic variants of the TbAT1 adenosine transporter from African trypanosomes in relapse infections following melarsoprol therapy.
    Matovu E; Geiser F; Schneider V; Mäser P; Enyaru JC; Kaminsky R; Gallati S; Seebeck T
    Mol Biochem Parasitol; 2001 Sep; 117(1):73-81. PubMed ID: 11551633
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overexpression of the putative thiol conjugate transporter TbMRPA causes melarsoprol resistance in Trypanosoma brucei.
    Shahi SK; Krauth-Siegel RL; Clayton CE
    Mol Microbiol; 2002 Mar; 43(5):1129-38. PubMed ID: 11918801
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of intermediates of methionine metabolism and nucleoside analogs on S-adenosylmethionine transport by Trypanosoma brucei brucei and a drug-resistant Trypanosoma brucei rhodesiense.
    Goldberg B; Rattendi D; Lloyd D; Sufrin JR; Bacchi CJ
    Biochem Pharmacol; 1998 Jul; 56(1):95-103. PubMed ID: 9698093
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The molecular arms race between African trypanosomes and humans.
    Pays E; Vanhollebeke B; Uzureau P; Lecordier L; Pérez-Morga D
    Nat Rev Microbiol; 2014 Aug; 12(8):575-84. PubMed ID: 24975321
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of mutant P2 adenosine transporter (TbAT1) gene in Trypanosoma brucei gambiense isolates from northwest Uganda using allele-specific polymerase chain reaction.
    Nerima B; Matovu E; Lubega GW; Enyaru JC
    Trop Med Int Health; 2007 Nov; 12(11):1361-8. PubMed ID: 18045263
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chimerization at the AQP2-AQP3 locus is the genetic basis of melarsoprol-pentamidine cross-resistance in clinical Trypanosoma brucei gambiense isolates.
    Graf FE; Baker N; Munday JC; de Koning HP; Horn D; Mäser P
    Int J Parasitol Drugs Drug Resist; 2015 Aug; 5(2):65-8. PubMed ID: 26042196
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A nucleoside transporter from Trypanosoma brucei involved in drug resistance.
    Mäser P; Sütterlin C; Kralli A; Kaminsky R
    Science; 1999 Jul; 285(5425):242-4. PubMed ID: 10398598
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification and Characterization of FTY720 for the Treatment of Human African Trypanosomiasis.
    Jones AJ; Kaiser M; Avery VM
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1859-61. PubMed ID: 26666915
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Innate lack of susceptibility of Ugandan Trypanosoma brucei rhodesiense to DL-alpha-difluoromethylornithine (DFMO).
    Iten M; Matovu E; Brun R; Kaminsky R
    Trop Med Parasitol; 1995 Sep; 46(3):190-4. PubMed ID: 8533023
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cynaropicrin: the first plant natural product with in vivo activity against Trypanosoma brucei.
    Zimmermann S; Kaiser M; Brun R; Hamburger M; Adams M
    Planta Med; 2012 Apr; 78(6):553-6. PubMed ID: 22331812
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trypanocidal activity of dicationic compounds related to pentamidine.
    Donkor IO; Assefa H; Rattendi D; Lane S; Vargas M; Goldberg B; Bacchi C
    Eur J Med Chem; 2001 Jun; 36(6):531-8. PubMed ID: 11525843
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Melarsoprol refractory T. b. gambiense from Omugo, north-western Uganda.
    Matovu E; Enyaru JC; Legros D; Schmid C; Seebeck T; Kaminsky R
    Trop Med Int Health; 2001 May; 6(5):407-11. PubMed ID: 11348535
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Melarsoprol Resistance in African Trypanosomiasis.
    Fairlamb AH; Horn D
    Trends Parasitol; 2018 Jun; 34(6):481-492. PubMed ID: 29705579
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of Trypanosoma brucei MRPA in melarsoprol susceptibility.
    Alibu VP; Richter C; Voncken F; Marti G; Shahi S; Renggli CK; Seebeck T; Brun R; Clayton C
    Mol Biochem Parasitol; 2006 Mar; 146(1):38-44. PubMed ID: 16343658
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trypanosome alternative oxidase, a potential therapeutic target for sleeping sickness, is conserved among Trypanosoma brucei subspecies.
    Nakamura K; Fujioka S; Fukumoto S; Inoue N; Sakamoto K; Hirata H; Kido Y; Yabu Y; Suzuki T; Watanabe Y; Saimoto H; Akiyama H; Kita K
    Parasitol Int; 2010 Dec; 59(4):560-4. PubMed ID: 20688188
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Occurrence of multiple drug resistance in Trypanosoma brucei rhodesiense isolated from sleeping sickness patients.
    Kagira JM; Maina N
    Onderstepoort J Vet Res; 2007 Mar; 74(1):17-22. PubMed ID: 17708149
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug resistance in African trypanosomiasis: the melarsoprol and pentamidine story.
    Baker N; de Koning HP; Mäser P; Horn D
    Trends Parasitol; 2013 Mar; 29(3):110-8. PubMed ID: 23375541
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular pharmacology of adenosine transport in Trypanosoma brucei: P1/P2 revisited.
    Geiser F; Lüscher A; de Koning HP; Seebeck T; Mäser P
    Mol Pharmacol; 2005 Sep; 68(3):589-95. PubMed ID: 15933219
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Uptake and mode of action of drugs used against sleeping sickness.
    Denise H; Barrett MP
    Biochem Pharmacol; 2001 Jan; 61(1):1-5. PubMed ID: 11137702
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In-vitro Anti-trypanosomal and Cytotoxicity Evaluation of 3-methyl-3,4-dihydroquinazolin-2(1H)-one Derivatives.
    Jesumoroti OJ; Beteck RM; Legoabe LJ
    Drug Res (Stuttg); 2021 Jul; 71(6):335-340. PubMed ID: 33535253
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.